Table 3.
Adjusted* odds ratios of intermediate and advanced liver fibrosis by liver disease markers for current alcohol use patterns, stratified by HCV status, the NOAH study
| Intermediate liver damage/fibrosis | Advanced liver fibrosis | |||||||
|---|---|---|---|---|---|---|---|---|
| ALT | AST | NAFLD-FS | APRI | FIB-4 | NAFLD-FS | APRI | FIB-4 | |
| Odds ratios (95% CI) | Odds ratios (95% CI) | |||||||
| TLFB hazardous ≥40/60 | ||||||||
| All | 3.33 (1.58, 7.02) | 5.74 (2.33, 14.10) | 3.31 (1.40, 7.85) | 2.44 (1.02, 5.81) | 1.79 (0.74, 4.32) | 4.08 (0.81, 20.60) | 15.87 (3.22, 78.12) | 6.76 (1.81, 25.33) |
| HCV+ | - | 6.98 (0.64, 75.60) | 0.45 (0.05, 4.00) | 1.06 (0.14, 8.11) | 1.52 (0.17, 13.93) | 6.48 (0.28, 149.68) | 67.55 (1.09, 765.63) | 3.68 (0.23, 60.33) |
| HCV− | 2.94 (1.35, 6.39) | 5.57 (2.15, 14.48) | 4.55 (1.76, 11.73) | 2.90 (1.18, 7.16) | 1.81 (0.71, 4.62) | 3.62 (0.56, 23.32) | 11.79 (2.17, 64.16) | 7.68 (1.90, 31.08) |
| AUDIT high risk >16 | ||||||||
| All | 1.53 (0.72, 3.29) | 3.12 (1.22, 7.99) | 1.24 (0.56, 2.75) | 1.38 (0.57, 3.37) | 0.76 (0.31, 1.88) | 1.40 (0.28, 7.07) | 7.07 (1.31, 38.26) | 5.83 (1.44, 23.68) |
| HCV+ | 5.18 (0.56, 48.25) | 8.81 (1.36, 57.19) | 0.73 (0.13, 4.27) | 2.78 (0.51, 14.93) | 0.49 (0.08, 2.90) | 2.37 (0.12, 48.21) | 4.43 (0.13, 147.70) | 2.46 (0.19, 31.60) |
| HCV− | 1.29 (0.57, 2.94) | 2.30 (0.80, 6.67) | 1.36 (0.58, 3.16) | 1.49 (0.55, 4.05) | 0.82 (0.31, 2.17) | 1.14 (0.18, 7.25) | 8.91 (1.56, 50.90) | 7.08 (1.60, 31.25) |
| PEth severe misuse >400 | ||||||||
| All | 2.05 (0.93, 4.52) | 3.90 (1.45, 10.49) | 5.51 (2.23, 13.62) | 3.75 (1.55, 9.07) | 3.96 (1.56, 10.07) | 8.43 (1.32, 53.72) | 17.52 (2.55, 120.5) | 17.75 (3.30, 95.63) |
| HCV+ | 0.29 (0.04, 2.10) | 0.63 (0.08, 5.13) | 26.09 (1.97, 345.82) | 1.40 (1.33, 1.48) | 16.57 (1.12, 244.2) | - | 0.41 (0.35, 0.49) | - |
| HCV− | 2.77 (1.23, 6.25) | 5.89 (2.03, 17.07) | 4.42 (1.71, 11.42) | 3.18 (3.12, 3.24) | 3.16 (1.17, 8.51) | 7.66 (1.18, 49.85) | 26.20 (25.71, 26.70) | 46.95 (6.15, 358.70) |
ALT = alanine aminotransferase; AST = aspartate aminotransferase; NAFLD-FS = non-alcoholic fatty liver disease fibrosis score; APRI = AST to platelet ratio index; FIB-4 = fibrosis-4.
*All models adjusted for age, sex, BMI, hepatitis-B virus status, smoking status, viral load and lifetime drinking history.